Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories has announced the acquisition of the Stugeron brand from Johnson & Johnson, a strategic move aimed at strengthening its portfolio in the therapeutic segment. Stugeron, a well-established product for vertigo and motion sickness, complements Dr. Reddy’s existing offerings and expands its presence in both domestic and international markets. Analysts note that this acquisition reflects the company’s ongoing focus on consolidating high-value brands, enhancing market share, and leveraging synergies in marketing and distribution.

Dr. Reddy’s Laboratories reported a marginal 1% increase in net profit for the first quarter of FY26, registering Rs. 1,410 crore, compared to Rs. 1,394 crore in the corresponding quarter last year. While the bottom line edged higher, the company's performance was shaped by steady growth in key international markets and improved product launches, tempered by rising costs and foreign exchange headwinds. Revenue from operations stood at Rs. 7,394 crore, reflecting resilient demand across therapeutic categories.

Dr. Reddy’s Laboratories has entered a strategic collaboration with international biotech firm Alvotech to co-develop and commercialize a biosimilar candidate targeting Keytruda (pembrolizumab), a leading immuno-oncology drug with global sales exceeding USD 29.5 billion in 2024. This partnership leverages the combined expertise of both companies in biosimilar innovation, aiming to expedite product development and broaden market access worldwide. The agreement entails joint responsibility for development, manufacturing, and cost-sharing, positioning Dr.

Two of India’s leading pharmaceutical companies—Dr. Reddy’s Laboratories and Lupin Ltd—are facing regulatory setbacks in the United States after initiating product recalls over quality control and labelling issues. The U.S. Food and Drug Administration (USFDA) flagged both firms in its recent enforcement report, citing Dr. Reddy’s for a labelling discrepancy in its antiepileptic injectable and Lupin for impurity-related concerns in an antidepressant formulation. These recalls, especially the Class I recall issued to Dr.